GSK completes acquisition of 35Pharma Inc.
London, UK, Apr. 15, 2026 — GSK plc (LSE/NYSE: GSK) announced the completion of its acquisition of 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specialising in the development of novel protein-based therapeutics. The acquisition includes HS235, a potential best-in-class molecule for the treatment of pulmonary hypertension (PH). HS235 targets the activin receptor signalling pathway, […]